Medical treatment of freezing of gait
Identifieur interne : 000D54 ( Main/Exploration ); précédent : 000D53; suivant : 000D55Medical treatment of freezing of gait
Auteurs : Nir Giladi [Israël]Source :
- Movement Disorders [ 0885-3185 ] ; 2008.
English descriptors
Abstract
Freezing of gait (FOG) is frequently considered as one of the dopamine‐resistant motor symptoms of Parkinsonism. Recent studies have clearly demonstrated that the Off‐related FOG is improved by levodopa (L‐dopa) or entacapone treatment. L‐dopa can decrease duration of each FOG episode as well as its frequency. On‐related FOGs are not common and difficult to diagnose. Only in the most advanced stages of the disease, FOGs are resistant to treatment as many other symptoms. Off‐related FOGs are likely to be improved by dopamine agonists (DAs), but this has never been looked at systematically. In contrast, DA treatment might provoke FOG, and in two pivotal studies when DAs were compared to L‐dopa in early stages of Parkinson's disease, the DA‐treated arms experienced more FOGs. MAO‐B inhibitors (selegiline and rasagiline) can decrease FOG frequency or severity, but its clinical significance is still unknown. L‐Threo‐DOPS has been reported to have a symptomatic beneficial effect in patients with pure freezing syndrome, but small‐scale, controlled trials in Parkinson's disease could not support those early observations. Botulinum toxin injected into the calf muscles has been suggested to have a symptomatic benefit. However, double‐blind, prospective studies could not support that early observation and increased fall risk in the injected patients has put this direction of treatment on hold. The potential benefit of amantadine, antidepressive drugs, acetylcholine esterase inhibitors, and methylphenidate on FOG has been studied in small‐scale studies, and there is a need for prospective studies to understand the future role of those drugs. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.21914
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Medical treatment of freezing of gait</title><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7BB5CAD4401EC01FAFC296C4D59B8B0C6EB946BD</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21914</idno><idno type="url">https://api.istex.fr/document/7BB5CAD4401EC01FAFC296C4D59B8B0C6EB946BD/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000569</idno><idno type="wicri:Area/Main/Curation">000494</idno><idno type="wicri:Area/Main/Exploration">000D54</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Medical treatment of freezing of gait</title><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv</wicri:regionArea><wicri:noRegion>Tel‐Aviv</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008">2008</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="supplement">S2</biblScope><biblScope unit="page" from="S482">S482</biblScope><biblScope unit="page" to="S488">S488</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7BB5CAD4401EC01FAFC296C4D59B8B0C6EB946BD</idno><idno type="DOI">10.1002/mds.21914</idno><idno type="ArticleID">MDS21914</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dopamine agonist</term><term>freezing of gait</term><term>levodopa</term><term>treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Freezing of gait (FOG) is frequently considered as one of the dopamine‐resistant motor symptoms of Parkinsonism. Recent studies have clearly demonstrated that the Off‐related FOG is improved by levodopa (L‐dopa) or entacapone treatment. L‐dopa can decrease duration of each FOG episode as well as its frequency. On‐related FOGs are not common and difficult to diagnose. Only in the most advanced stages of the disease, FOGs are resistant to treatment as many other symptoms. Off‐related FOGs are likely to be improved by dopamine agonists (DAs), but this has never been looked at systematically. In contrast, DA treatment might provoke FOG, and in two pivotal studies when DAs were compared to L‐dopa in early stages of Parkinson's disease, the DA‐treated arms experienced more FOGs. MAO‐B inhibitors (selegiline and rasagiline) can decrease FOG frequency or severity, but its clinical significance is still unknown. L‐Threo‐DOPS has been reported to have a symptomatic beneficial effect in patients with pure freezing syndrome, but small‐scale, controlled trials in Parkinson's disease could not support those early observations. Botulinum toxin injected into the calf muscles has been suggested to have a symptomatic benefit. However, double‐blind, prospective studies could not support that early observation and increased fall risk in the injected patients has put this direction of treatment on hold. The potential benefit of amantadine, antidepressive drugs, acetylcholine esterase inhibitors, and methylphenidate on FOG has been studied in small‐scale studies, and there is a need for prospective studies to understand the future role of those drugs. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Israël</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D54 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D54 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7BB5CAD4401EC01FAFC296C4D59B8B0C6EB946BD
|texte= Medical treatment of freezing of gait
}}
| This area was generated with Dilib version V0.6.23. |  |